DEF: Core Labs Sets 2026 Annual Meeting Agenda, Details Executive Pay

Sentiment:

Proxy Statement


Core Laboratories Inc. announces its 2026 annual meeting of shareholders to address director re-election, auditor ratification, and advisory vote on executive compensation, alongside disclosures on financial performance and geopolitical risks.

Worse than expectedThe company applied negative discretion to executive officers' annual cash incentive payouts, resulting in only 36% of the earned bonus being paid, despite performance metrics justifying higher payouts. This indicates management's cautious view on broader financial performance and geopolitical uncertainties.The EPS Yield was at the 33rd percentile of the Compensation Peer Group, leading to a zero payout for this metric in the annual incentive calculation, suggesting underperformance in this key area relative to peers.Revenue growth was only 0.5%, which is very low and indicates minimal top-line expansion, falling short of robust growth expectations.

Summary

  • The 2026 Annual Meeting of Shareholders will be held on Tuesday, May 12, 2026, at 9:00 a.m. Central Daylight Time (CDT) at the Hotel Zaza, Memorial City, Houston, Texas.
  • Shareholders will vote on the re-election of two current Class I Directors (Harvey Klingensmith and Curtis Anastasio) to serve until the 2029 annual meeting.
  • The appointment of KPMG LLP as the company's independent registered public accountants for the year ending December 31, 2026, will be put to a shareholder vote for ratification.
  • An advisory vote will be held to approve the compensation philosophy, policies, and procedures, and the compensation of the company's named executive officers (NEOs) for 2025.
  • For 2025, the company reported a revenue increase of 0.5%, an operating margin of 10.7%, and an EPS Yield of 4.7%.
  • Return on Invested Capital (ROIC) was approximately 9.8% in 2025, placing the company at the 68th percentile of the Bloomberg Oil and Gas Services Comp Group.
  • Safety performance improved significantly in 2025, with a Total Recordable Injury Rate of 0.19 (down from 0.50 in 2024) and a Lost Time Injury Rate of 0.03 (down from 0.21 in 2024).
  • Executive compensation for 2025 included no salary adjustments for NEOs since October 2023, and a negative discretion was applied to annual cash incentive payouts, resulting in only 36% of the earned bonus being paid.
  • The company received 94.3% shareholder approval for its executive compensation program at the 2025 annual meeting.
  • A clawback policy for performance-based compensation was adopted on November 8, 2023, and a recovery analysis for immaterial prior period errors determined no recovery was required from covered executives.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While operational and ROIC performance show strength relative to peers, the low revenue growth, underperformance in EPS yield, and management's decision to significantly reduce executive bonuses due to broader financial and geopolitical uncertainties temper the overall positive sentiment.

Positives

  • Achieved year-over-year improvement in financial and operational performance for certain key metrics in 2025.
  • Ranked in the top-quartile for operating margin and Return on Invested Capital (ROIC) when compared to its peers.
  • ROIC of approximately 9.8% was at the 68th percentile of the Bloomberg Oil and Gas Services Comp Group in 2025, indicating strong capital efficiency.
  • Demonstrated significant improvement in safety metrics with a Total Recordable Injury Rate of 0.19 in 2025, down from 0.50 in 2024, and a Lost Time Injury Rate of 0.03 in 2025, down from 0.21 in 2024.
  • Achieved an industry-leading ranking among its peer group on several key sustainability indices in 2025, reflecting a commitment to sustainable and responsible growth.
  • Maintained strong shareholder support for its executive compensation program, with 94.3% of votes cast approving the program at the 2025 annual meeting.
  • Continued commitment to 100% performance-based Long-Term Incentive (LTI) Awards for Named Executive Officers (NEOs), aligning executive interests with shareholder value.
  • All current non-executive Directors are in compliance with the Compensation Committee's minimum stock ownership requirements.
  • All Directors participated in 100% of the 2025 Board meetings and committee meetings on which they served, indicating strong engagement and oversight.

Negatives

  • Negative discretion was applied to Named Executive Officers (NEOs) under the annual cash incentive plan, resulting in a payout of only 36% of the earned bonus, despite performance metrics justifying higher payouts, due to a broader assessment of financial performance and geopolitical uncertainties.
  • Revenue increase was only 0.5% in 2025, indicating very modest top-line growth.
  • The EPS Yield was at the 33rd percentile of the Compensation Peer Group, resulting in a zero score for this metric in the annual incentive calculation, indicating underperformance relative to peers in this area.
  • Geopolitical conflicts (Russia-Ukraine, Middle East) and U.S. trade policies, including tariffs, have caused disruptions and instability in the movement and trading patterns of crude oil and derived products.
  • The effective closure of the Strait of Hormuz due to military conflict in Iran has exacerbated maritime trade flows of crude oil, impacting demand for the company's associated laboratory assay services.
  • Near-term volatility in commodity prices meaningfully raises the level of uncertainty for the company's business outlook.
  • Immaterial errors in prior period financial statements, including a $4.7 million misclassification and a $5.4 million adjustment to retained earnings, required correction in the 2025 Form 10-K, although they did not trigger clawback provisions.

Risks

  • Geopolitical conflicts, specifically the ongoing conflicts between Russia and Ukraine and the military conflict between the United States, Israel, and Iran, cause disruptions and instability in the movement and trading patterns of crude oil and derived products.
  • The effective closure of the Strait of Hormuz due to military conflict in Iran significantly exacerbates maritime trade flows of crude oil and derived products, potentially stranding approximately 20% of global crude oil production and directly impacting demand for laboratory assay services.
  • Uncertainty surrounding the impact of global trade negotiations and the imposition of tariffs could lead to a surplus in supply, causing global inventories of crude oil to rise and putting downward pressure on crude oil prices.
  • Near-term volatility in commodity prices meaningfully raises the level of uncertainty, particularly affecting demand for smaller-scale, short-cycle crude oil development projects and well completion services in the U.S. onshore market.
  • Disruptions to traditional maritime supply chains and the trading of crude oil and derived products due to ongoing conflicts and associated sanctions could adversely impact business in affected regions.
  • A steeper natural decline rate in existing fields represents a dominant long-term supply risk, requiring sustained upstream investment of approximately $540 to $570 billion per year to prevent disruptive declines and avoid supply shortages and price volatility.

Future Outlook

The company maintains a constructive long-term outlook for continued growth in the demand for oil and natural gas. It anticipates that large-scale international oil and gas projects will be more resilient to near-term crude oil price volatility, with client projects expected to continue as planned outside the U.S. Conversely, activity levels for smaller-scale, short-cycle crude oil development projects, particularly in the U.S. onshore market, are expected to be more sensitive to decreases or continued volatility in crude oil prices. The volume of associated laboratory services is projected to align with global crude oil trading and movement. The International Energy Agency's data suggests a sustained upstream investment of approximately $540 to $570 billion per year is necessary to prevent disruptive declines and avoid future supply shortages and price volatility.

Management Comments

  • "The Company's outlook for continued growth in the demand for oil and natural gas remains constructive."
  • "While the Company believes the fundamentals for energy-related services remain stable, near-term volatility in commodity prices meaningfully raises the level of uncertainty."
  • "The Company is monitoring developments with respect to the ongoing military conflict with Iran, including the impact on global commodity prices and potential shipping and logistics disruptions, which could affect our customers and their activity levels in the region."
  • "The Company continues to focus on large-scale core analyses and reservoir fluids characterization studies in most oil-producing regions across the globe."
  • "The Company believes that activity levels associated with smaller-scale, short-cycle crude oil development projects will be more sensitive to a decrease and/or continued volatility of crude-oil prices."
  • "Outside the U.S., large-scale international oil and gas projects are expected to be more resilient to the near-term volatility of crude-oil prices, and the Company anticipates client projects will continue to be executed as planned."

Industry Context

StockSavvy.ai notes that Core Laboratories' constructive long-term outlook for oil and gas demand aligns with broader industry expectations for continued energy needs, despite near-term volatility. The emphasis on large-scale international projects and carbon capture initiatives reflects a strategic adaptation to both traditional energy demands and emerging sustainability trends within the sector. The geopolitical instability in the Middle East and its impact on crude oil trade, particularly the Strait of Hormuz, highlights a significant industry-wide challenge affecting supply chains and commodity prices, which Core Labs acknowledges as a source of uncertainty. The IEA's projected annual upstream investment of $540-$570 billion underscores the critical need for sustained capital in the industry to counter natural decline rates and ensure future supply, positioning Core Labs' services as essential for optimizing these investments.

Comparison to Industry Standards

  • Core Laboratories' 2025 ROIC of 9.8% at the 68th percentile of the Bloomberg Oil and Gas Services Comp Group indicates strong capital efficiency relative to peers like Bristow Group Inc., NOV Inc., and Weatherford International, suggesting effective asset utilization.
  • The company's significant improvement in safety metrics (Total Recordable Injury Rate of 0.19 and Lost Time Injury Rate of 0.03 in 2025) demonstrates a commitment to operational excellence that likely positions it favorably against industry averages, comparable to leading safety performers in the oilfield services sector.
  • The executive compensation program's emphasis on 100% performance-based equity awards and a clawback policy aligns with best practices in corporate governance, similar to those adopted by other publicly traded energy service companies to link executive pay directly to shareholder value and mitigate risk.
  • The 94.3% shareholder approval for the 2025 say-on-pay vote suggests that Core Laboratories' compensation philosophy and practices are well-received by investors, indicating alignment with market expectations for executive remuneration in the energy sector, especially when compared to the typical 70-80% approval rates seen across the S&P 500.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
President, Chief Executive Officer and ChairmanDavid Demshur (Chairman and CEO)Lawrence BrunoMay 20, 2020Succession

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Board StructureThe company maintains a single-tier board currently consisting of seven directors divided among three classes, with each class elected for a three-year term. Lawrence Bruno serves as both CEO and Chairman, a structure the company believes is effective and common in its industry.NAMaintains continuity and integrated leadership, aligning with industry practice while ensuring a staggered board for stability.
Lead Director RoleMartha Z. Carnes has served as Lead Director since the 2020 annual meeting, responsible for setting the agenda for and leading all executive sessions of the independent directors, and providing feedback to the Chairman.2020 Annual MeetingEnhances independent oversight and provides a clear channel for independent director feedback, strengthening corporate governance.
Director IndependenceSix of the seven Board members (Messrs. Temeng, Klingensmith, Anastasio, Martinovich and Mmes. Carnes, Murray) are determined to be independent under applicable SEC and NYSE standards.NAEnsures strong independent oversight and compliance with regulatory requirements, promoting objective decision-making.
Mandatory Resignation PolicyA mandatory resignation policy for directors in uncontested elections requires each nominee to submit an irrevocable resignation letter as a condition of nomination, which is deemed tendered if they fail to achieve more votes for election than votes withheld.NAIncreases accountability for directors in uncontested elections and provides the Board with flexibility to address shareholder dissent effectively.
Mandatory Retirement PolicyDirectors must retire from the Board prior to the next annual meeting following their 77th birthday, subject to waivers or extensions that may be granted by the Board in exceptional circumstances.NABalances continuity with renewal on the Board, ensuring a mix of experienced perspectives while allowing for fresh insights.
Related Person Transactions PolicyThe Audit Committee is charged with reviewing and approving related person transactions exceeding $120,000, ensuring terms are fair and reasonable to the company and at least as favorable as those available from non-related parties.NAMitigates potential conflicts of interest and protects shareholder value in dealings with related parties, promoting transparency.
Insider Trading PolicyThe company has a written policy prohibiting hedging or monetization transactions, trading in company-based derivative securities, purchasing company securities on margin, and pledging company securities as collateral for debt obligations for all Directors, Officers, and employees.NAReinforces ethical conduct, prevents conflicts of interest, and aligns insider interests with long-term shareholder value by restricting speculative trading.
Non-Executive Director Deferred Compensation PlanApproved in August 2025, this plan allows non-executive directors to defer vesting of all or part of their restricted stock awards and receipt of cash retainers to a future date, with deferred amounts held as company common stock and distributed upon retirement.August 2025Provides flexibility for directors' compensation planning and further aligns their long-term financial interests with the company's stock performance.
Clawback PolicyAdopted on November 8, 2023, this policy is applicable to performance-based compensation paid to executive officers, allowing for recoupment in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements.November 8, 2023Enhances accountability, reinforces the pay-for-performance philosophy, and ensures compliance with SEC and NYSE rules (Section 10D and Rule 10D-1).

Related Party Transactions

  • There were no transactions that occurred during fiscal year 2025 in which the amount involved exceeded $120,000, and in which any director, director nominee, named executive officer, holder of more than 5% of common stock, or any immediate family member had a direct or indirect material interest.

Stakeholder Impact

  • Shareholders are directly impacted by the proposals at the annual meeting, including director elections, auditor ratification, and the advisory vote on executive compensation, which influence governance and financial oversight. Financial performance metrics like ROIC and EPS yield directly affect shareholder returns, while geopolitical risks introduce volatility to their investment.
  • Employees benefit from competitive health and welfare benefits, 401(k) plans, and nonqualified deferred compensation plans. Improved safety rates enhance the work environment, and the clawback policy promotes accountability among executive leadership.
  • Customers' demand for the company's laboratory assay services is directly influenced by crude oil trading patterns, geopolitical conflicts, and commodity price volatility, which can affect their activity levels and project execution.
  • Suppliers may face potential disruptions to maritime supply chains due to geopolitical conflicts and associated sanctions, which could impact the company's operational needs and, consequently, its relationships with suppliers.
  • Creditors assess the company's financial health, operating margin, and ROIC performance to evaluate its ability to meet debt obligations, making these metrics crucial for maintaining favorable credit terms.

Next Steps

  • Shareholders will vote on the re-election of two Class I Directors, ratification of KPMG as independent auditor, and an advisory vote on executive compensation at the Annual Meeting on May 12, 2026.
  • Payment of the 2025 annual cash incentive bonus to Named Executive Officers (NEOs) is scheduled for the second quarter of 2026.
  • Restricted shares will be awarded to non-executive Directors effective April 1, 2026, with vesting scheduled for April 1, 2027.
  • The company will continue to monitor geopolitical developments, including the Middle East conflict, and their impact on global commodity prices and shipping/logistics.
  • Ongoing focus on large-scale core analyses and reservoir fluids characterization studies will continue across global oil-producing regions.
  • The company will continue its involvement in projects to capture and sequester carbon dioxide.
  • The Compensation Committee will routinely assess compensation policies and practices on an annual basis.
  • Shareholder proposals intended for inclusion in the 2027 Annual Meeting proxy statement must be received by December 1, 2026.
  • Notice of shareholder proposals and director nominations (not included in the proxy statement) for the 2027 Annual Meeting must be received between January 12, 2027, and February 11, 2027.

Key Dates

DateDescription
2019-03-01Lawrence Bruno, Christopher S. Hill, and Gwendolyn Y. Gresham entered into their initial employment agreements.
2020-05-20Lawrence Bruno succeeded David Demshur as Chairman of the Board and Chief Executive Officer.
2020-10-01Mark D. Tattoli received an RSAP grant.
2020-12-31Beginning of the performance graph period for common stock, S&P 500 Index, S&P 500 Oil & Gas Equipment & Service Index, and Philadelphia Oil Service Index (OSX).
2021-08-01Mark D. Tattoli received an RSAP grant.
2021-10-15Employment agreements for Messrs. Bruno, Hill, and Ms. Gresham were amended and restated; Mark D. Tattoli entered into his employment agreement.
2023-02-16Grants of 250,680 restricted performance share units were made to current NEOs (2023 PSAP awards).
2023-10-02Effective date of Rule 10D-1 for the company's clawback policy.
2023-11-08The Board adopted a clawback policy applicable to performance-based compensation.
2024-01-10Closing price of the company's stock used for the 2024 non-executive director restricted share grant calculation.
2024-02-01Employment agreements for Messrs. Bruno, Hill, and Tattoli and Ms. Gresham were amended and restated.
2024-02-15PSAP grants were made to NEOs.
2024-04-01Effective date of the 2024 non-executive director restricted share grant.
2025-01-01Beginning of the three-year performance period for 2025 PSAP awards.
2025-01-14Closing price of the company's stock used for the 2025 non-executive director restricted share grant calculation.
2025-02-13Grants of 337,388 restricted performance shares were made to current NEOs (2025 PSAP awards).
2025-04-01Effective date of the 2025 non-executive director restricted share grant.
2025-04-29BlackRock, Inc. filed Amendment No. 3 to Schedule 13G.
2025-05-01The 2024 non-executive director restricted shares vested.
2025-08-01The Board approved the adoption of a deferred compensation plan for non-executive directors.
2025-11-14Ariel Investment, LLC filed Amendment No. 8 to Schedule 13G.
2025-12-31End of the fiscal year for the filing; end of the three-year performance period for 2023 PSAP awards; end of the performance graph period.
2026-02-12Earnest Partners, LLC filed Amendment No. 12 to Schedule 13G.
2026-02-17Disciplined Growth Investors Inc filed Amendment No. 5 to Schedule 13G.
2026-02-28Onset of military conflict between the United States, Israel, and Iran.
2026-03-14The Audit Committee concluded that the financial statements for the 2024 fiscal year should be revised in the 2025 Form 10-K.
2026-03-18Record date for shareholders entitled to vote at the 2026 Annual Meeting.
2026-03-23The company filed its Annual Report on Form 10-K for the year ended December 31, 2025.
2026-03-31Proxy statement and accompanying proxy card first made available to shareholders; date of the Notice of Annual Meeting of Shareholders.
2026-04-01The 2025 non-executive director restricted shares will vest; effective date for the 2026 non-executive director restricted share grant.
2026-05-07Deadline for voting by Internet or phone for shares held in a Plan.
2026-05-11Deadline for voting by Internet or phone for directly held shares.
2026-05-12Date of the 2026 Annual Meeting of Shareholders.
2026-12-01Deadline for shareholder proposals (Rule 14a-8) for inclusion in the 2027 Annual Meeting proxy statement.
2026-12-31Year ending for KPMG's appointment as independent registered public accountants.
2027-01-12Earliest date for notice of shareholder proposals and director nominations (not included in proxy statement) for the 2027 Annual Meeting.
2027-02-11Latest date for notice of shareholder proposals and director nominations (not included in proxy statement) for the 2027 Annual Meeting.
2027-04-01The 2026 non-executive director restricted shares will vest.
2027-12-31End of the three-year performance period for 2025 PSAP awards.

Recommendation

hold

While Core Laboratories demonstrates strong operational performance, high ROIC relative to peers, and robust corporate governance, the low revenue growth of 0.5% and underperformance in EPS yield are concerning. The management's decision to apply negative discretion to executive bonuses due to broader financial and geopolitical uncertainties signals a cautious outlook. The significant geopolitical risks, particularly the Middle East conflict and its impact on crude oil trade, introduce substantial near-term volatility. Given these mixed signals—strong efficiency and governance against slow growth and high external risks—a 'hold' recommendation is appropriate for investors to monitor how these risks and growth challenges evolve.

Keywords

Core Laboratories, SEC Filing, Proxy Statement, Annual Meeting, Executive Compensation, Corporate Governance, Oil & Gas Services, Energy Industry, Shareholder Vote, Board of Directors, KPMG, ROIC, ESG, Geopolitical Risk, Crude Oil Prices, Sustainability, Financial Performance, Shareholder Return, Oilfield Services

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.